Skip to main content
Erschienen in: PharmacoEconomics 11/2009

01.11.2009 | Review Article

Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program

verfasst von: Dr Sripen Tantivess, Yot Teerawattananon, Anne Mills

Erschienen in: PharmacoEconomics | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Capacity is limited in the developing world to conduct cost-effectiveness analysis (CEA) of health interventions. In Thailand, there have been concerted efforts to promote evidence-based policy making, including the introduction of economic appraisals within health technology assessment (HTA). This paper reviews the experience of this lower middle-income country, with an emphasis on the creation of the Health Intervention and Technology Assessment Program (HITAP), including its mission, management structures and activities.
Over the past 3 decades, several HTA programmes were implemented in Thailand but not sustained or developed further into a national institute. As a response to increasing demands for HTA evidence including CEA information, the HITAP was created in 2007 as an affiliate unit of a semi-autonomous research arm of the Ministry of Public Health. An advantage of this HTA programme over previous initiatives was that it was hosted by a research institute with long-term experience in conducting health systems and policy research and capacity building of its research staff, and excellent research and policy networks. To deal with existing impediments to conducting health economics research, the main strategies of the HITAP were carefully devised to include not only capacity strengthening of its researchers and administrative staff, but also the development of essential elements for the country’s health economic evaluation methodology. These included, for example, methodological guidelines, standard protocols and benchmarks for resource allocation, many of which have been adopted by national policy-making bodies including the three major public health insurance plans. Networks and collaborations with domestic and foreign institutes have been sought as a means of resource mobilization and exchange. Although the HITAP is well financed by a number of government agencies and international organizations, the programme is vulnerable to shortages of qualified research staff, as most staff work on a part-time or temporary basis.
To enhance the utilization of its research findings by policy makers, practitioners and consumers, the HITAP has adopted the principles of technical excellence, policy relevance, transparency, effective communication and participation of key stakeholders. These principles have been translated into good practice at every step of HTA management. In 2007 and 2008, the HITAP carried out assessments of a wide range of health products, medical procedures and public health initiatives. Although CEA and other economic evaluation approaches were employed in these studies, the tools and underlying efficiency goal were considered inadequate to provide complete information for prioritization. As suggested by official stakeholders, some of the projects investigated broader issues of management, feasibility, performance and socio-political implications of interventions. As yet, it is unclear what role HITAP research and associated recommendations have played in policy decisions.
It is hoped that the lessons drawn on the creation of the HITAP and its experience during the first 2 years, as well as information on its main strategies and management structures, may be helpful for other resource-constrained countries when considering how best to strengthen their capacity to conduct economic appraisals of health technologies and interventions.
Fußnoten
1
Exchange rate (mid 2007): Bt30 per $US1.
 
Literatur
1.
Zurück zum Zitat Neumann PJ. Using cost-effectiveness analysis to improve health care: opportunities and barriers. Oxford: Oxford University Press, 2005 Neumann PJ. Using cost-effectiveness analysis to improve health care: opportunities and barriers. Oxford: Oxford University Press, 2005
2.
Zurück zum Zitat Doherty J, Kamae I, Lee KKC, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health 2004; 7 (2): 118–32PubMedCrossRef Doherty J, Kamae I, Lee KKC, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health 2004; 7 (2): 118–32PubMedCrossRef
3.
Zurück zum Zitat Iglesias CP, Drummond MF, Rovira J. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005; 21 (1): 1–14PubMedCrossRef Iglesias CP, Drummond MF, Rovira J. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005; 21 (1): 1–14PubMedCrossRef
4.
Zurück zum Zitat Tarn Y, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific Region. Value Health 2008; 11 Suppl. 1: S137–55CrossRef Tarn Y, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific Region. Value Health 2008; 11 Suppl. 1: S137–55CrossRef
5.
Zurück zum Zitat Tangcharoensathien V, Wibupolprasert S, Nitayaramphong S. Knowledge-based changes to health systems: the Thai experience in policy development. Bull World Health Organ 2004; 82: 750–6PubMed Tangcharoensathien V, Wibupolprasert S, Nitayaramphong S. Knowledge-based changes to health systems: the Thai experience in policy development. Bull World Health Organ 2004; 82: 750–6PubMed
6.
Zurück zum Zitat Teerawattananon Y, Russell S. A difficult balancing act: policy actors perspectives on using economic evaluation to inform health-care coverage decisions under the Universal Health Insurance Coverage scheme in Thailand. Value Health 2008; 11 Suppl. 1: S52–60CrossRef Teerawattananon Y, Russell S. A difficult balancing act: policy actors perspectives on using economic evaluation to inform health-care coverage decisions under the Universal Health Insurance Coverage scheme in Thailand. Value Health 2008; 11 Suppl. 1: S52–60CrossRef
8.
Zurück zum Zitat Tangcharoensathien V. National health account in Thailand. Alexandria (VA): Consultation on NHA and External Resource Flow for the Ellison Institute for World Health, 2005 Tangcharoensathien V. National health account in Thailand. Alexandria (VA): Consultation on NHA and External Resource Flow for the Ellison Institute for World Health, 2005
10.
Zurück zum Zitat Ministry of Public Health. Thailand Health Profile 2001–2004. Nonthaburi: Ministry of Public Health, 2005 Ministry of Public Health. Thailand Health Profile 2001–2004. Nonthaburi: Ministry of Public Health, 2005
11.
Zurück zum Zitat Teerawattananon Y, Tangcharoensathien V, Tantivess S, et al. Health sector regulation in Thailand: recent progress and the future agenda. Health Policy 2003; 63: 323–38PubMedCrossRef Teerawattananon Y, Tangcharoensathien V, Tantivess S, et al. Health sector regulation in Thailand: recent progress and the future agenda. Health Policy 2003; 63: 323–38PubMedCrossRef
12.
Zurück zum Zitat The Working Group for Drug Policy and Laws Study. National drug policy. In: Wibulpolprasert S, Chokevivat V, Tantivess S, editors. Thai drug system [in Thai]. Nonthaburi: International Health Policy Program, 2002 The Working Group for Drug Policy and Laws Study. National drug policy. In: Wibulpolprasert S, Chokevivat V, Tantivess S, editors. Thai drug system [in Thai]. Nonthaburi: International Health Policy Program, 2002
13.
Zurück zum Zitat World Health Organization, Regional Office for South-East Asia. Health implications of the economic crisis in the South-East Asia region. Report of a Regional Consultation; 1998 Mar 23–25; Bangkok World Health Organization, Regional Office for South-East Asia. Health implications of the economic crisis in the South-East Asia region. Report of a Regional Consultation; 1998 Mar 23–25; Bangkok
14.
Zurück zum Zitat Subcommittee for National List of Essential Medicine Development. Minutes of the Subcommittee meeting; 2008 Jan 30 [in Thai]. Nonthaburi: Food and Drug Administration, 2008 Subcommittee for National List of Essential Medicine Development. Minutes of the Subcommittee meeting; 2008 Jan 30 [in Thai]. Nonthaburi: Food and Drug Administration, 2008
15.
Zurück zum Zitat Wibupolprasert S. The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the National List of Essential Drugs. J Med Assoc Thai 2008; 91 Suppl. 2: S1–3 Wibupolprasert S. The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the National List of Essential Drugs. J Med Assoc Thai 2008; 91 Suppl. 2: S1–3
16.
Zurück zum Zitat Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 2007; 25 (6): 467–79PubMedCrossRef Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 2007; 25 (6): 467–79PubMedCrossRef
17.
Zurück zum Zitat Chaikledkaew U, Lertpitakpong C, Orrawattanakul Y, et al. Survey on the current human capacity and future needs in economic evaluation in Thailand [in Thai]. Nonthaburi: Health Intervention and Technology Assessment Program, 2008 Chaikledkaew U, Lertpitakpong C, Orrawattanakul Y, et al. Survey on the current human capacity and future needs in economic evaluation in Thailand [in Thai]. Nonthaburi: Health Intervention and Technology Assessment Program, 2008
18.
Zurück zum Zitat Pitayarangsarit S, Tangcharoensathien V. Capacity development for health policy and systems research: experience and lessons from Thailand. In: Green A, Bennett S, editors. Sound choices: enhancing capacity for evidence-informed health policy. Geneva: World Health Organization, 2007: 147–66 Pitayarangsarit S, Tangcharoensathien V. Capacity development for health policy and systems research: experience and lessons from Thailand. In: Green A, Bennett S, editors. Sound choices: enhancing capacity for evidence-informed health policy. Geneva: World Health Organization, 2007: 147–66
19.
Zurück zum Zitat Tomson G, Sundbom R. The Technology Assessment and Social Security in Thailand (TASSIT) project report. Stockholm: Division of International Health (IHCAR), Karolinska Institute, 1999 Tomson G, Sundbom R. The Technology Assessment and Social Security in Thailand (TASSIT) project report. Stockholm: Division of International Health (IHCAR), Karolinska Institute, 1999
20.
21.
Zurück zum Zitat Tantivess S. Integrating IHPP research into policy decisions: 10th anniversary of the International Health Policy Program (19982008). Nonthaburi: International Health Policy Program, 2008 Tantivess S. Integrating IHPP research into policy decisions: 10th anniversary of the International Health Policy Program (19982008). Nonthaburi: International Health Policy Program, 2008
22.
Zurück zum Zitat Nansunanont S, Tantivess S, Yothasamut J, et al. The development of health technology assessment in Thailand, 1996–2006 [in Thai]. Nonthaburi: Health Intervention and Technology Assessment, 2008 Nansunanont S, Tantivess S, Yothasamut J, et al. The development of health technology assessment in Thailand, 1996–2006 [in Thai]. Nonthaburi: Health Intervention and Technology Assessment, 2008
23.
Zurück zum Zitat Tangcharoensathien V, Kamolratanakul P. Making sensible rationing: the use of economic evidence and the need for methodological standards. J Med Assoc Thai 2008; 91 Suppl. 2: S4–7 Tangcharoensathien V, Kamolratanakul P. Making sensible rationing: the use of economic evidence and the need for methodological standards. J Med Assoc Thai 2008; 91 Suppl. 2: S4–7
24.
Zurück zum Zitat Tantivess S. Policy making and roles of health technology assessment. J Med Assoc Thai 2008; 91 Suppl. 2: S88–99 Tantivess S. Policy making and roles of health technology assessment. J Med Assoc Thai 2008; 91 Suppl. 2: S88–99
25.
Zurück zum Zitat Hanvoravongchai P. Health system and equity perspectives in health technology assessment. J Med Assoc Thai 2008; 91 Suppl. 2: S74–87 Hanvoravongchai P. Health system and equity perspectives in health technology assessment. J Med Assoc Thai 2008; 91 Suppl. 2: S74–87
26.
Zurück zum Zitat Lertpitakpong C, Chaikledkaew U, Thavorncharoensap M, et al. A determination of topics for health technology assessment in Thailand: making decision makers involved. J Med Assoc Thai 2008; 91 Suppl. 2: S100–9 Lertpitakpong C, Chaikledkaew U, Thavorncharoensap M, et al. A determination of topics for health technology assessment in Thailand: making decision makers involved. J Med Assoc Thai 2008; 91 Suppl. 2: S100–9
28.
Zurück zum Zitat Tangcharoensathien V, editor. Development of an optimal policy strategy for prevention and control of cervical cancer in Thailand. Nonthaburi: International Health Policy Program and Health Intervention and Technology Assessment Program, 2008 [online]. Available from URL: (http://www.hitap.net/index_en.php) [Accessed 2008 Nov 10] Tangcharoensathien V, editor. Development of an optimal policy strategy for prevention and control of cervical cancer in Thailand. Nonthaburi: International Health Policy Program and Health Intervention and Technology Assessment Program, 2008 [online]. Available from URL: (http://​www.​hitap.​net/​index_​en.​php) [Accessed 2008 Nov 10]
29.
Zurück zum Zitat Sauerborn R, Nitayarumphong S, Gerhardus A. Strategies to enhance the use of health systems research for health sector reforms. Trop Med Int Health 1999; 4 (12): 827–35PubMedCrossRef Sauerborn R, Nitayarumphong S, Gerhardus A. Strategies to enhance the use of health systems research for health sector reforms. Trop Med Int Health 1999; 4 (12): 827–35PubMedCrossRef
30.
Zurück zum Zitat Macintyre S, Chalmers I, Horton R, et al. Using evidence to informhealth policy: case study. BMJ 2001; 322 (7280): 222–5PubMedCrossRef Macintyre S, Chalmers I, Horton R, et al. Using evidence to informhealth policy: case study. BMJ 2001; 322 (7280): 222–5PubMedCrossRef
32.
Zurück zum Zitat Yothasamut J, Tantivess S. Management of health technology assessment in foreign countries [in Thai]. Nonthaburi: Health Intervention and Technology Assessment Program, 2008 Yothasamut J, Tantivess S. Management of health technology assessment in foreign countries [in Thai]. Nonthaburi: Health Intervention and Technology Assessment Program, 2008
33.
Zurück zum Zitat Teerawattananon Y, Tantivess S, Yothasamut J, et al. Historical development of health technology assessment in Thailand. Int J Technol Assess Health Care 2009; 25 Suppl. 1: 241–52PubMedCrossRef Teerawattananon Y, Tantivess S, Yothasamut J, et al. Historical development of health technology assessment in Thailand. Int J Technol Assess Health Care 2009; 25 Suppl. 1: 241–52PubMedCrossRef
34.
Zurück zum Zitat Singer ME. Cost-effectiveness analysis: developing nations left behind. Pharmacoeconomics 2008; 26 (5): 359–61PubMedCrossRef Singer ME. Cost-effectiveness analysis: developing nations left behind. Pharmacoeconomics 2008; 26 (5): 359–61PubMedCrossRef
35.
Zurück zum Zitat Hailey DM. Health technology assessment in Canada: diversity and evolution. MJA 2007; 187 (5): 286–8PubMed Hailey DM. Health technology assessment in Canada: diversity and evolution. MJA 2007; 187 (5): 286–8PubMed
36.
Zurück zum Zitat Jackson TJ. Health technology assessment in Australia: challenges ahead. MJA 2007; 187 (5): 262–4PubMed Jackson TJ. Health technology assessment in Australia: challenges ahead. MJA 2007; 187 (5): 262–4PubMed
37.
Zurück zum Zitat Young J. Research and policy: parallel universe? London: Overseas Development Institute, 2003 Young J. Research and policy: parallel universe? London: Overseas Development Institute, 2003
Metadaten
Titel
Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program
verfasst von
Dr Sripen Tantivess
Yot Teerawattananon
Anne Mills
Publikationsdatum
01.11.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 11/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/11314710-000000000-00000

Weitere Artikel der Ausgabe 11/2009

PharmacoEconomics 11/2009 Zur Ausgabe